Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Psychotic major depression (PMD) is found to be a relatively common psychiatric condition that affects up to nearly 20% of patients with major depression. Previous studies by our group have shown rapid reversal of psychotic symptoms in some PMD patients treated with mifepristone, in addition to restoring a more normal afternoon cortisol release. The rationale for treating patients with PMD with a glucocorticosteroid receptor antagonist is further discussed. In total, 30 patients with PMD were treated with either 600 mg/day mifepristone or placebo for 8 days in a randomized double-blind manner. The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment. Cortisol and ACTH were measured hourly from 1800 to 0900 at baseline and after 8 days of treatment. Significantly, more patients in the mifepristone group (seven of 15) showed a 50% or greater decline on the BPRS positive symptom subscale, an index of psychotic symptoms, as compared to the placebo group (two of 15). Patients who received mifepristone had lower HDRS and BPRS scores at study completion compared to those who received placebo, but these differences were not statistically significant. In addition, mifepristone significantly elevated cortisol and ACTH levels and steepened ascending slopes from 1800 to 0100 and from 0100 to 0900 as compared to placebo. Clinical and biological effects of mifepristone were comparable among males and females. Age was found to significantly and positively correlate with changes in cortisol and ACTH. These results suggest that short-term use of mifepristone may be effective in the treatment of PMD and may re-regulate the HPA axis. Additional blinded studies are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
In the citing paper
“Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…procedures included the Structured Clinical Interview for the DSM-IV (SCID; First et al, 1997), the 21-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1980), the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1961), and clinical laboratory tests (complete blood count,…”
MethodThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment.”
MethodBrain corticosteroid receptor balance and homeostatic control
de Kloet, E. R. (1991) · Frontiers in Neuroendocrinology · Cited by 842
Disrupted 24-hour patterns of cortisol secretion in psychotic depression
Sachar, E. J. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750310011002 · Cited by 775 · cited 1×
“…they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundLupien, S. J., Gillin, C. J., & Hauger, R. L. (1999) · Behavioral Neuroscience · doi:10.1037/0735-7044.113.3.420 · Cited by 561 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultDecreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultFunctional biology of intestinal goblet cells
Specian, R. D., & Oliver, M. G. (1991) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1991.260.2.c183 · Cited by 467
The pharmacological treatment of delusional depression
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.430 · Cited by 357
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356 · cited 2×
“Most notably, they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Self-citation
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM IV-TR Axis I Disorders—Patient Edition (SCID-I/P, 2/2001 revision). American Psychiatric Press, Inc.: Washington, DC.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
“The place of antiglucocorticoid treatment with mifepristone is unclear, as although there have been positive studies (DeBattista et al., 2006; Flores et al., 2006), three phase III studies failed to meet primary outcomes (Nihalani and Schwartz, 2007; http:// www.”
BackgroundStress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects
Mahar, I., Bambico, F. R., Mechawar, N., & Nobrega, J. N. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.11.009 · Cited by 694
The glucocorticoid receptor: Pivot of depression and of antidepressant treatment?
Anacker, C., Zunszain, P. A., Carvalho, L. A., & Pariante, C. M. (2011) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.03.007 · Cited by 592
“Other studies however, have only found improvements in psychotic but not in depressive symptoms in patients with psychotic major depression (DeBattista et al., 2006; Flores et al., 2006).”
BackgroundResultCognitive impairment associated to HPA axis hyperactivity after maternal separation in rats
Aisa, B., Tordera, R., Lasheras, B., Del Río, J., & Ramírez, M. J. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2006.12.013 · Cited by 539
“In this regard, in clinical studies, it has been recently shown that by regulating the HPA axis, mifepristone may be effective in the treatment of psychotic major depression (Flores et al., 2006) and bipolar disorder (Young et al.”
BackgroundCorticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats
Vendruscolo, L. F., Barbier, E., Schlosburg, J. E., Misra, K. K., Whitfield, T. W., Logrip, M. L., Rivier, C., Repunte-Canonigo, V., Zorrilla, E. P., Sanna, P. P., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0069-12.2012 · Cited by 319
“, 2012), and mifepristone has some promise for treating dysregulated mood (Flores et al., 2006; Nihalani and Schwartz, 2007; Blasey et al., 2009).”
BackgroundAdolescent Stress–Induced Epigenetic Control of Dopaminergic Neurons via Glucocorticoids
Niwa, M., Jaaro-Peled, H., Tankou, S., Seshadri, S., Hikida, T., Matsumoto, Y., Cascella, N. G., Kano, S.-I., Ozaki, N., Nabeshima, T., et al. (2013) · Science · doi:10.1126/science.1226931 · Cited by 318
Cortisol and depression: three questions for psychiatry
Herbert, J. (2013) · Psychological Medicine · doi:10.1017/s0033291712000955 · Cited by 301
“Some report rapid resolution of symptoms (Belanoff et al. 2001 ; Flores et al. 2006), others less dramatic results (Simpson et al.”
BackgroundResultMondelli, V., Dazzan, P., Hepgul, N., Di Forti, M., Aas, M., D'Albenzio, A., Di Nicola, M., Fisher, H., Handley, R., Marques, T. R., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.013 · Cited by 278
“Therefore, it is possible that the capability of antipsychotics to decrease diurnal cortisol secretion plays a role in their therapeutic action (Flores et al., 2006).”
Cortisol and major depressive disorder-translating findings from humans to animal models and Back
Nandam, L. S., Brazel, M., Zhou, M., & Jhaveri, D. J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00974 · Cited by 265
“org 5 rather than depressive, symptoms (85, 86).”
BackgroundHormonal Treatments for Major Depressive Disorder: State of the Art
Dwyer, J. B., Aftab, A., Radhakrishnan, R., Widge, A., Rodriguez, C. I., Carpenter, L. L., Nemeroff, C. B., McDonald, W. M., Kalin, N. H., & APA Council of Research Task Force on Novel Biomarkers and Treatments (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19080848 · Cited by 252
“Two double-blind trials showed a significant difference in the proportion of responders to mifepristone compared with placebo (response was defined as a reduction of 50% in score on the positive symptom subscale of the Brief Psychiatric Rating Scale [BPRS] [58] and a 30% reduction in the full BPRS score [59]).”
BackgroundGap Junction Dysfunction in the Prefrontal Cortex Induces Depressive-Like Behaviors in Rats
Sun, J.-D., Liu, Y., Yuan, Y.-H., Li, J., & Chen, N.-H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.319 · Cited by 258
Oomen, C. A., Mayer, J. L., De Kloet, E. R., Joëls, M., & Lucassen, P. J. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05972.x · Cited by 232
Mantella, R. C., Butters, M. A., Amico, J. A., Mazumdar, S., Rollman, B. L., Begley, A. E., Reynolds, C. F., & Lenze, E. J. (2008) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.03.002 · Cited by 222
“This premise has been the source of a number of studies evaluating the efficacy of glucocorticoid inhibitors (Belanoff et al., 2001, 2002; Jahn et al., 2004; Flores et al., 2006) and glucocorticoid receptor antagonists (Bachmann et al., 2003; Johnson et al., 2007) as anti-depressants.”
BackgroundAisa, B., Tordera, R., Lasheras, B., Del Río, J., & Ramírez, M. J. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.05.011 · Cited by 206
de Kloet, E. R., DeRijk, R. H., & Meijer, O. C. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0403 · Cited by 193
Glucocorticoids: Mood, Memory, and Mechanisms
Wolkowitz, O. M., Burke, H., Epel, E. S., & Reus, V. I. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04980.x · Cited by 181
Butts, K. A., Weinberg, J., Young, A. H., & Phillips, A. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111746108 · Cited by 182
“Similarly, short-term intervention with RU-38486 has also proven to be beneficial in the treatment for psychotic depression (52).”
BackgroundMayer, J. L., Klumpers, L., Maslam, S., De Kloet, E. R., Joëls, M., & Lucassen, P. J. (2006) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2006.01455.x · Cited by 181
DeBattista, C., Belanoff, J., Glass, S., Khan, A., Horne, R. L., Blasey, C., Carpenter, L. L., & Alva, G. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.034 · Cited by 162
Watson, S., Gallagher, P., Porter, R. J., Smith, M. S., Herron, L. J., Bulmer, S., Young, A. H., & Ferrier, I. N. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.029 · Cited by 145
Hypothalamic‐Pituitary‐Adrenocortical Axis: Neuropsychiatric Aspects
Jacobson, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130036 · Cited by 144
Pharmacological treatment for psychotic depression
Wijkstra, J., Lijmer, J., Burger, H., Cipriani, A., Geddes, J., & Nolen, W. A. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004044.pub4 · Cited by 137
The HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
Childhood trauma and cognitive function in first-episode affective and non-affective psychosis
Aas, M., Dazzan, P., Fisher, H. L., Morgan, C., Morgan, K. D., Reichenberg, A., Zanelli, J., Fearon, P., Jones, P. B., Murray, R. M., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.03.017 · Cited by 140
“For example, both bipolar disorder and psychotic depressionhavebeenassociatedwith impaired cognitive function in the context of hyperactivity of the HPA axis, to a much larger extent than schizophrenia (Belanoff et al., 2001; Flores et al., 2006; Gallagher et al., 2005; Watson et al., 2004; Young et al., 2004).”
BackgroundWulsin, A. C., Herman, J. P., & Solomon, M. B. (2010) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2010.01.011 · Cited by 119
“, 2008) and therapeutic effects for the treatment of psychotic depression (Flores et al., 2006) with 4—8day treatment.”
Revsin, Y., Rekers, N. V., Louwe, M. C., Saravia, F. E., De Nicola, A. F., de Kloet, E. R., & Oitzl, M. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.136 · Cited by 119
“The treatment schedule was based on the efficacy of mifepristone in the treatment of psychosis (van der Lely et al, 1991) and psychotic depression (Flores et al, 2006), and previous animal studies using corticosterone injections and chronic stress (Mayer Table 2 Effects of Diabetes and Mifepristone…”
Shibata, M., Katsuyama, M., Onodera, T., Ehama, R., Hosoi, J., & Tagami, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.237 · Cited by 116
The Interface of Pain and Mood Disturbances in the Rheumatic Diseases
Goldenberg, D. L. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.005 · Cited by 131
Jiao, W., Lin, J., Deng, Y., Ji, Y., Liang, C., Wei, S., Xi, J., & Yan, F. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03312-3 · Cited by 143
Tronel, S., & Alberini, C. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.009 · Cited by 116
“RU 38486 has been reported to be safe and effective when given to patients with psychotic depression and bipolar disorder (Flores et al 2006,DeBattista and Belanoff 2006), but it is unclear whether acute doses of systemic RU 38486 would successfully impede reconsolidation of traumatic memories in…”
BackgroundGalvão, A. C. D. M., de Almeida, R. N., Silva, E. A. D. S., Freire, F. A. M., Palhano-Fontes, F., Onias, H., Arcoverde, E., Maia-de-Oliveira, J. P., de Araújo, D. B., Lobão-Soares, B., et al. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00185 · Cited by 108
“Although there is great evidence that normalization of HPA axis function is essential for the successful treatment of depressive patients (89, 94, 95) differently of our hypothesis, herein changes in cortisol levels induced by ayahuasca were not correlated with improvement in depressive symptoms observed from D1 to D7…”
Bosscher, K. D., Craenenbroeck, K. V., Meijer, O. C., & Haegeman, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.11.076 · Cited by 106
The use of mifepristone in the treatment of neuropsychiatric disorders
DeBattista, C., & Belanoff, J. K. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.02.006 · Cited by 103
Molecular substrates of schizophrenia: homeostatic signaling to connectivity
Landek-Salgado, M. A., Faust, T. E., & Sawa, A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.141 · Cited by 96
Ago, Y., Arikawa, S., Yata, M., Yano, K., Abe, M., Takuma, K., & Matsuda, T. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.08.026 · Cited by 110
Aznar, S., & Knudsen, G. M. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100390 · Cited by 94
“Reduced GR receptor levels have been found in depressed patients [129] and mifepristone, a GR receptor antagonist, can successfully treat psychotic depression [130, 131].”
Involvement of Adenosine A2A Receptors in Depression and Anxiety
Yamada, K., Kobayashi, M., & Kanda, T. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00015-5 · Cited by 108
Progesterone receptor modulators and the endometrium: changes and consequences†
Horne, F. M., & Blithe, D. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm023 · Cited by 99
“The antiglucocorticoid properties of mifepristone have provided a rationale for its use to treat neuropsychiatric disorders associated with abnormalities in the hypothalamic–pituitary axis (Wolkowitz and Reus, 1999; Belanoff et al., 2002; Pomara et al., 2002; Young et al., 2004; Simpson et al., 2005; Flores et al., 20…”
BackgroundAntiglucocorticoid treatments for mood disorders
Gallagher, P., Malik, N., Newham, J., Young, A. H., Ferrier, I. N., & Mackin, P. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005168.pub2 · Cited by 90
RetractedWu, L., Han, H., Wang, Q., Hou, H., Tong, H., Yan, X., & Zhou, J. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301386 · Cited by 92
Iijima, M., Ito, A., Kurosu, S., & Chaki, S. (2010) · Brain Research · doi:10.1016/j.brainres.2010.08.078 · Cited by 100
Yamada, K., Kobayashi, M., Mori, A., Jenner, P. G., & Kanda, T. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.022 · Cited by 93
Lesuis, S. L., Weggen, S., Baches, S., Lucassen, P. J., & Krugers, H. J. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0101-2 · Cited by 85
“It has further been tested in preliminary studies on (aspects of) AD 26 and psychotic depression 27,28 (see ref.”
A review on linking stress, depression, and insulin resistance via low-grade chronic inflammation
Mehdi, S., Wani, S. U. D., Krishna, K. L., Kinattingal, N., & Roohi, T. F. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101571 · Cited by 127
“…and Triiodothyronine Helpful in treating and activating the thyroid gland; be a potentially promising therapy due to the linkage between endocrine dysfunction and depression [122] Mifepristone Brought a rapid reduction in psychotic symptoms in patients with psychotic depression [131, 132].”
BackgroundNeuronal actions of glucocorticoids: Focus on depression
Yu, S., Holsboer, F., & Almeida, O. F. X. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2007.09.014 · Cited by 93
Block, T. S., Kushner, H., Kalin, N., Nelson, C., Belanoff, J., & Schatzberg, A. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.01.008 · Cited by 78
Self-citationPucak, M. L., Carroll, K. A. L., Kerr, D. A., & Kaplin, A. L. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.2/mpucak · Cited by 89
Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression
Blasey, C. M., Block, T. S., Belanoff, J. K., & Roe, R. L. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182239191 · Cited by 73
Schüle, C., Baghai, T. C., Eser, D., & Rupprecht, R. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.52 · Cited by 73
Hypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy
Wulsin, A. C., Solomon, M. B., Privitera, M., Danzer, S. C., & Herman, J. P. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.05.015 · Cited by 78
The role of mineralocorticoid receptor function in treatment-resistant depression
Juruena, M. F., Pariante, C. M., Papadopoulos, A. S., Poon, L., Lightman, S., & Cleare, A. J. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113499205 · Cited by 70
“The GR antagonist mifepristone (RU486) exerts therapeutic effects in the treatment of cognitive dysfunction in bipolar disorder (Young et al., 2004), but the data on core depressive symptoms in psychotic depression are less promising (Flores et al., 2006).”
BackgroundTaubenfeld, S. M., Riceberg, J. S., New, A. S., & Alberini, C. M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.005 · Cited by 71
“In addition, it has been studied in clinical trials for treatment of psychotic depression (42-46), Alzheimer’s Disease (47-49), schizophrenia (50) and bipolar disorder (51).”
Microglia and HPA axis in depression: An overview of participation and relationship
Pereira, G. C., Piton, E., dos Santos, B. M., Ramanzini, L. G., Camargo, L. F. M., da Silva, R. M., & Bochi, G. V. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1939154 · Cited by 74
Glucocorticoid antagonists in neuropsychotic disorders
Schatzberg, A. F., & Lindley, S. E. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.001 · Cited by 69
Self-citationBlasey, C. M., DeBattista, C., Roe, R., Block, T., & Belanoff, J. K. (2009) · Contemporary Clinical Trials · doi:10.1016/j.cct.2009.03.001 · Cited by 61
“Two recently published randomized clinical trials demonstrated that patients receiving mifepristone were more likely to have a rapid and sustained reduction of their psychotic symptoms [11,12].”
BackgroundThe role of glucocorticoids in emotional memory reconsolidation
Drexler, S. M., & Wolf, O. T. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.11.008 · Cited by 67
About Stress Hormones and Resilience to Psychopathology
De Kloet, E. R. (2008) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2008.01707.x · Cited by 59
Duval, F., Lebowitz, B. D., & Macher, J. P. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/fduval · Cited by 75
Hu, P., Oomen, C., van Dam, A.-M., Wester, J., Zhou, J.-N., Joëls, M., & Lucassen, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046224 · Cited by 58
“A similar quick switch may explain the rather rapid beneficial effects of mifepristone observed in a small sample of patients with psychotic depression [12,14,54,55].”
Wigmore, E. M., Clarke, T.-K., Howard, D. M., Adams, M. J., Hall, L. S., Zeng, Y., Gibson, J., Davies, G., Fernandez-Pujals, A. M., Thomson, P. A., et al. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.148 · Cited by 56
Pharmacological treatment for psychotic depression
Kruizinga, J., Liemburg, E. J., Burger, H., Cipriani, A., Geddes, J. R., Robertson, L., Vogelaar, B., & Nolen, W. A. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004044.pub5 · Cited by 72
Loi, M., Sarabdjitsingh, R. A., Tsouli, A., Trinh, S., Arp, M., Krugers, H. J., Karst, H., van den Bos, R., & Joëls, M. (2017) · eneuro · doi:10.1523/eneuro.0253-17.2017 · Cited by 54
“MIF discriminates well between GR and mineralocorticoid receptors (MRs; Moguilewsky and Philibert, 1984; Flores et al., 2006; Johanssen and Allolio, 2007).”
BackgroundGlucocorticoid action and the development of selective glucocorticoid receptor ligands
Cole, T. J. (2006) · Biotechnology annual review · doi:10.1016/s1387-2656(06)12008-6 · Cited by 68
Spiga, F., Harrison, L. R., Wood, S. A., Atkinson, H. C., MacSweeney, C. P., Thomson, F., Craighead, M., Grassie, M., & Lightman, S. L. (2007) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2007.01605.x · Cited by 53
Golier, J. A., Caramanica, K., Michaelides, A. C., Makotkine, I., Schmeidler, J., Harvey, P. D., & Yehuda, R. (2015) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2015.11.001 · Cited by 53
“ifepristone has been shown to have beneficial effects on mood nd/or cognition in other neuropsychiatric disorders including psyhotic depression and Alzheimer’s disease (Belanoff et al., 2001; hu et al., 2001; Pomara et al., 2002; Young et al., 2004; Simpson t al., 2005; Flores et al., 2006; Watson et al., 2012).”
Kling, M. A., Coleman, V. H., & Schulkin, J. (2009) · Depression and Anxiety · doi:10.1002/da.20546 · Cited by 52
“Flores et al.([3]) conducted a randomized double-blind study examining the effects of mifepristone on patients diagnosed with psychotic major depression.”
BackgroundInfluentialSchatzberg, A. F. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.916414 · Cited by 51
Self-citationClark, R. D., Ray, N. C., Williams, K. R., Blaney, P. M., Ward, S., Crackett, P. H., Hurley, C. A., Dyke, H. J., Clark, D. E., Lockey, P. M., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.01.027 · Cited by 51
Zhang, Y.-P., Wang, H.-Y., Zhang, C., Liu, B.-P., Peng, Z.-L., Li, Y.-Y., Liu, F.-M., & Song, C. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.03.033 · Cited by 49
Hormone treatment of depression
Joffe, R. T. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.1/rjoffe · Cited by 50
Resetting the Stress System with a Mifepristone Challenge
Dalm, S., Karssen, A. M., Meijer, O. C., Belanoff, J. K., & de Kloet, E. R. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-018-0614-5 · Cited by 49
Salvat-Pujol, N., Labad, J., Urretavizcaya, M., de Arriba-Arnau, A., Segalàs, C., Real, E., Ferrer, A., Crespo, J. M., Jiménez-Murcia, S., Soriano-Mas, C., et al. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2016.11.007 · Cited by 47
Block, T., Petrides, G., Kushner, H., Kalin, N., Belanoff, J., & Schatzberg, A. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000744 · Cited by 47
Self-citationRefining and integrating schizophrenia pathophysiology – Relevance of the allostatic load concept
Misiak, B., Frydecka, D., Zawadzki, M., Krefft, M., & Kiejna, A. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.06.004 · Cited by 54
Reduced glucocorticoid receptors: consequence or cause of depression?
Neigh, G. N., & Nemeroff, C. B. (2006) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2006.03.002 · Cited by 57
“Also of note are recent reports that mifepristone, a glucocorticoid receptor antagonist, can successfully treat the psychotic component of delusional depression [4], characterized by profound HPA axis hyperactivity.”
BackgroundKarst, H., & Joëls, M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301296 · Cited by 55
“…and (ii) if so, whether this can be normalized by 4-days treatment with the GR-antagonist RU 38486, a compound that was recently described to rapidly ameliorate symptoms of bipolar or psychotic depression in humans (Belanoff et al, 2001; Young et al, 2004; Simpson et al, 2005; Flores et al, 2006).”
BackgroundResultInfluentialLombardo, G., Enache, D., Gianotti, L., Schatzberg, A. F., Young, A. H., Pariante, C. M., & Mondelli, V. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104420 · Cited by 45
“, 2004) focused on afternoon blood collection, one study (Flores et al., 2006) analysed blood collected”
BackgroundMethodSelf-citationYau, J. L. W., Noble, J., Thomas, S., Kerwin, R., Morgan, P. E., Lightman, S., Seckl, J. R., & Pariante, C. M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301389 · Cited by 46
“Third, drugs that directly regulate HPA axis activity have therapeutic effects in affective disorders (Nemeroff and Owens, 2002; Young et al, 2004; Flores et al, 2006).”
BackgroundDISC1 mouse models as a tool to decipher gene-environment interactions in psychiatric disorders
Cash-Padgett, T. V., & Jaaro-Peled, H. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00113 · Cited by 52
Papilloud, A., Veenit, V., Tzanoulinou, S., Riccio, O., Zanoletti, O., de Suduiraut, I. G., Grosse, J., & Sandi, C. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0110-0 · Cited by 50
Hu, P., Liu, J., Zhao, J. J., Qi, X., Qi, C.-C., Lucassen, P. J., & Zhou, J.-N. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.98 · Cited by 47
Considerations on the ICD-11 Classification of Psychotic Depression
Østergaard, S. D., Rothschild, A. J., Uggerby, P., Munk‐Jørgensen, P., Bech, P., & Mors, O. N. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000334487 · Cited by 46
Early life stress-induced alterations in rat brain structures measured with high resolution MRI
Sarabdjitsingh, R. A., Loi, M., Joëls, M., Dijkhuizen, R. M., & van der Toorn, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185061 · Cited by 48
Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia
Gallagher, P., Watson, S., Dye, C. E., Young, A. H., & Ferrier, I. N. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.12.005 · Cited by 45
“It has also been demonstrated that changes in mean (6 pm to 1 am) ACTH following mifepristone are correlated with improvement in positive symptoms (trend level) and significantly so with improvement in BPRS total score, such that greater improvement was seen in patients with greater decreases in mean (6 pm to 1 am) AC…”
BackgroundPost-traumatic stress disorder: emerging concepts of pharmacotherapy
Baker, D. G., Nievergelt, C. M., & Risbrough, V. B. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902972494 · Cited by 40
“Small studies (n = 30) of psychotic depression and bipolar disorder thus far using a non-selective glucocorticoid receptor antagonist mifepristone (RU-486), otherwise known as the morning after pill, are reported to show promise in reducing cognitive disruption and psychosis [138,139].”
BackgroundSchulkin, J. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.4/jschulkin · Cited by 39
Metyrapone in treatment-resistant depression
Sigalas, P. D., Garg, H., Watson, S., McAllister-Williams, R. H., & Ferrier, I. N. (2012) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312436597 · Cited by 40
“…findings in the initial open studies [Belanoff et al. 2001, 2002; Simpson et al. 2005] and randomized controlled trials [DeBattista et al. 2006; Flores et al. 2006] have been followed by a larger negative trial [Blasey et al. 2011], which used reduction in psychotic symptoms as the outcome…”
ResultProgression of intervention-focused research for Gulf War illness
Chester, J. E., Rowneki, M., Van Doren, W., & Helmer, D. A. (2019) · Military Medical Research · doi:10.1186/s40779-019-0221-x · Cited by 38
Jakovcevski, M., Schachner, M., & Morellini, F. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.034 · Cited by 40
“Consistently, clinical studies indicate that pharmacological GR antagonism may be a useful treatment of major depression in humans (DeBattista and Belanoff, 2006; Flores et al., 2006).”
BackgroundBiomarkers in development of psychotropic drugs
Wiedemann, K. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/kwiedemann · Cited by 37
Targeting glucocorticoid receptor signaling pathway for treatment of stress-related brain disorders
Göver, T., & Ślęzak, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00654-w · Cited by 48
Kunzel, H. E., Ackl, N., Hatzinger, M., Held, K., Holsboer‐Trachsler, E., Ising, M., Kaschka, W. P., Kasper, S. F., Konstantinidis, A., Sonntag, A., et al. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.10.004 · Cited by 38
“A reduced HPA activity was also described in patients with delusional depression who showed a good response in psychotic features to treatment with the glucocorticoid antagonist mifepristone (Flores et al., 2006).”
BackgroundLlorens-Martín, M., & Trejo, J. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028376 · Cited by 44
“Short-term treatment with mifepristone produces antidepressant effects in animal models of depression [105] and in clinical trials [103] [104].”
Howell, K. R., & Pillai, A. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.05.011 · Cited by 36
“It has been shown that short-term use of Mifepristone, a GR antagonist (RU38486), is effective in the treatment of psychotic major depression via re-regulating the HPA axis (Flores et al., 2006).”
BackgroundDing, Y., Wei, Z., Yan, H., & Guo, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732157 · Cited by 34
“Additional well-designed RCTs with prolonged follow-up periods investigating HPA-modulating treatments in different depression subtypes are needed.”
BackgroundInfluential
Metadata
- Authors
- Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F.
- Affiliations
- Stanford University (US)
- Stanford Medicine (US)
- Corresponding author
- Flores, Benjamin H
- Venue
- Neuropsychopharmacology
- Published
- 2005-09-14
- Volume
- 31
- Issue
- 3
- Pages
- 628-636
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2081535802
- Cited by
- 203
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 9 · 2015: 10 · 2014: 12 · 2013: 13 · 2012: 11
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (MH50604)
- National Institute of Mental Health (R0-1MH50604, MH-47573, R01MH050604, R01 MH 47573, R01MH047573, T32MH019938)
- National Center for Research Resources (M01RR000070)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, psychotic depression, glucocorticoid receptor antagonist, hypothalamic-pituitary-adrenal axis, cortisol, ACTH, depression treatment
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Psychiatric Status Rating Scales, Receptors, Glucocorticoid, Sex Characteristics, Mifepristone, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.